---
title: 'Everolimus plus reduced calcineurin inhibitor prevents <em>de novo</em> anti-HLA
  antibodies and humoral rejection in kidney transplant recipients: 12-month results
  from the ATHENA study'
date: '2024-07-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38993866/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240712181613&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: The EVR regimen was comparable to MPA regimen with an extremely
  low incidence of dnDSA over 1 year of ...'
disable_comments: true
---
CONCLUSION: The EVR regimen was comparable to MPA regimen with an extremely low incidence of dnDSA over 1 year of ...